voglibose + metformin (Zinnia Life Sciences)

Zinivog M is a fixed-dose combination of voglibose, an alpha-glucosidase inhibitor, and metformin hydrochloride, a biguanide antihyperglycemic agent. Developed by Zinnia Life Sciences, it is indicated for the management of type 2 diabetes mellitus, particularly to control postprandial and fasting blood glucose levels. Voglibose acts locally in the small intestine to delay carbohydrate digestion and absorption, thereby reducing post-meal blood sugar spikes. Metformin works primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.

Brand names

Zinivog MZinivog M 0.2Zinivog m 0.3Zinivog-M 0.3Zinivog-M0.3Zinivog-M-0.3

Other names

voglibose + metforminvoglibose + metformin hydrochloridevoglibose and metforminvoglibose and metformin hydrochloridevoglibose/metforminvoglibose/metformin hydrochloride